

  
**TotalVisc™**  
Viscoelastic System



## COMPLETE SOLUTION. TOTAL PROTECTION.

The Viscoelastic System offering the next generation complete solution with both mechanical and chemical protection provided by ClearVisc™ and StableVisc™.

### FREE RADICAL PROTECTION

With two dual action formulations, ClearVisc™ and StableVisc™ create a strong physical barrier, providing mechanical protection and superior free radical eradication compared to other OVDs tested in a laboratory study.<sup>1,2,\*</sup>

### TOTAL PROTECTION


No other dual pack OVD system in the U.S. provides this unique complete solution, utilizing the protection of sorbitol in both ClearVisc™, dispersive and StableVisc™, cohesive.

### LARGEST FILL VOLUME

TotalVisc™ leads the U.S. dual pack OVD market in fill volume of device with 1 mL of ClearVisc™ and 1 mL StableVisc™.

\*Compared to ProVisc, Viscoat, Healon Pro, Healon Endocoat, AmVisc, Amvisc Plus.

**BAUSCH + LOMB**



**ORDER NUMBER** TVISC20

**TotalVisc™ includes one 1.0 mL of StableVisc™ and one 1.0 mL of ClearVisc™**



Set up your TotalVisc™ trial



**ORDER NUMBER:** DVISC10  
**SIZE:** 1.0 mL  
**VISCOSITY:** 40,000  
**MOLECULAR WEIGHT (DALTONS):** <1.0 million  
**COMPOSITION:** 2.5% HA, 4% Sorbitol  
**COHESION:** Dispersive  
**OSMOLALITY:** 330  
**CANNULA SIZE:** 25G



**ORDER NUMBER:** SVISC10  
**SIZE:** 1.0 mL  
**VISCOSITY:** 50,000  
**MOLECULAR WEIGHT (DALTONS):** 2.1 million  
**COMPOSITION:** 1.0% HA, 4% Sorbitol  
**COHESION:** Cohesive  
**OSMOLALITY:** 340  
**CANNULA SIZE:** 27G

1. New Ophthalmic Viscosurgical Device (OVD) with Enhanced Hydroxyl Radical Scavenging Act (v0. 1)
2. Francesco Maugeri, Adriana Maltese, Keith W. Ward & Claudio Bucolo (2007) Hydroxyl Radical Scavenging Activity of a New Ophthalmic Viscosurgical Device, Curr Eye Res. 32:2, 105-111, DOI: 10.1080/02713680601147716

## Indications and Important Safety Information for ClearVisc, StableVisc and TotalVisc OVDs

**INDICATIONS:** ClearVisc, StableVisc and TotalVisc OVDs are indicated for use as surgical aids in ophthalmic anterior segment procedures including: Extraction of a cataract; Implantation of an intraocular lens (IOL)

**CONTRAINDICATIONS:** There are no contraindications to the use of ClearVisc, StableVisc and TotalVisc when used as a surgical aid in ophthalmic anterior segment procedures.

**PRECAUTIONS:** Precautions normally considered during anterior segment procedures are recommended. Pre-existing glaucoma may place patients at risk for increases in intraocular pressure from the OVD during the early postoperative period.

### WARNINGS:

- Do not use if the sterile barrier has been breached. Sterility cannot be guaranteed, and the patient will be at increased risk for infection.
- Do not use the OVD in subjects with known allergies to any of its components.
- An excess quantity of OVD should not be used. Excess OVD can cause increased intraocular pressure.
- The OVD should be removed from the anterior chamber at the end of surgery to prevent or minimize postoperative intraocular pressure increases (spikes). OVD remaining in the eye can cause increased intraocular pressure.
- If the postoperative intraocular pressure increases above expected values, corrective therapy should be administered. Increased intraocular pressure may lead to inflammation or vision loss.

- Do not re-use the cannula. Even after cleaning and rinsing, resterilized cannula could release particulate matter as the OVD is injected. It is recommended that a single-use disposable cannula be used when administering the OVD. Reuse may cause eye inflammation.
- If any particulate matter is observed, it should be removed by irrigation and/or aspiration. Particulate matter left in the eye may cause increased IOP or Light scattering /obstruction.
- Store at 2° to 8°C (36° to 46°F). Protect from freezing. The shelf life of ClearVisc, StableVisc and TotalVisc is not guaranteed if it is not properly stored.

**ADVERSE REACTIONS:** Sodium hyaluronate is a natural component of tissues within the body and is generally well tolerated in human eyes. Transient postoperative inflammatory reactions and increases in intraocular pressure have been reported. Inflammation may result from increased intraocular pressure caused by use of the OVD. Intraocular inflammation, i.e., toxic anterior segment syndrome (TASS), has been attributed to OVDs. Furthermore, vision loss may be possible as a result of increased intraocular pressure and inflammation.

**ATTENTION:** Refer to the Directions for Use labeling for a complete listing of indications, warnings and precautions, clinical trial information, etc.

**CAUTION:** Federal (USA) law restricts this device to the sale by or on the order of a physician.